Published in J Urol on December 14, 2009
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
The prostate health index selectively identifies clinically significant prostate cancer. J Urol (2014) 2.68
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol (2014) 1.42
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
Toward the detection of prostate cancer in urine: a critical analysis. J Urol (2012) 1.13
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One (2013) 1.09
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
Urinary biomarkers for prostate cancer: a review. Asian J Androl (2013) 1.02
Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00
The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol (2014) 0.89
Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr (2012) 0.83
Markers for detection of prostate cancer. Cancers (Basel) (2010) 0.82
PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol (2015) 0.82
Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models. J Urol (2013) 0.82
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Risk stratification of prostate cancer in the modern era. Curr Opin Urol (2015) 0.80
Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. Rev Urol (2011) 0.80
Heterogeneity in active surveillance protocols worldwide. Rev Urol (2014) 0.78
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer. Biomed Res Int (2015) 0.76
Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol (2013) 0.76
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75
Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl (2015) 0.75
Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. Prostate Cancer Prostatic Dis (2017) 0.75
The role of prostate cancer biomarkers in undiagnosed men. Curr Opin Urol (2017) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Complications after prostate biopsy: data from SEER-Medicare. J Urol (2011) 5.40
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol (2012) 4.11
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol (2006) 2.34
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal masses. Urology (2013) 2.28
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol (2011) 2.20
Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol (2009) 2.18
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16